The quarter came in below the market’s bar. Published estimates were roughly $4.04 billion of revenue and $0.32 of adjusted diluted EPS; Kenvue delivered $3.955 billion and $0.31, respectively.
| Metric | Q2 2026 | Q2 2025 | Published expectation |
|---|---|---|---|
| Net sales | $3.955B | $3.839B | ~$4.04B |
| Organic sales growth | 1.6% | — | — |
| Adjusted diluted EPS | $0.31 | $0.29 | ~$0.32 |
| Adjusted operating margin | 22.1% | 22.7% | — |
| Free cash flow, first six months | $1.0B | $0.8B | — |
Underlying demand improved, but not enough to clear expectations. Reported sales rose 3.0%, yet organic growth was only 1.6%, with 1.4 percentage points coming from foreign exchange. Skin Health and Beauty was the clear bright spot at 3.7% organic growth, while Self Care grew just 0.6% and Essential Health 1.1% (Organic sales change table). The return to U.S. organic growth is constructive, but the overall result still fell short of the published revenue bar.
Profitability was the main quality issue. Adjusted gross margin declined to 60.2% from 60.9%, and adjusted operating margin fell to 22.1% from 22.7%, despite cost savings. Inflation, tariffs, unfavorable transactional foreign exchange, and higher brand support offset productivity gains (Adjusted operating income reconciliation). The lower margins help explain why adjusted EPS missed even though reported net income increased to $456 million from $420 million (Income Statement; Adjusted diluted EPS reconciliation).
Cash generation was materially better, but it does not erase the earnings miss. First-half operating cash flow increased to $1.2 billion from $1.0 billion, while free cash flow rose to $1.0 billion from $0.8 billion as capital spending declined to $0.2 billion (Free cash flow reconciliation). That supports liquidity ahead of the planned Kimberly-Clark transaction, but debt remained high at $8.5 billion and cash was unchanged at $1.1 billion (Net debt table).
The FDA approval and merger timing are incremental positives, not surprises that change the quarter’s read. Tylenol with Naproxen adds a potentially useful OTC product, while the Kimberly-Clark combination remains expected to close in the fourth quarter of 2026; both are strategic developments, but neither offsets the near-term combination of a revenue miss, adjusted EPS miss, and weaker margins (Product development; Pending transaction). Net: modestly worse than expected operational performance, partly cushioned by stronger cash flow and improving U.S. demand.
Read the original 8-K on SEC EDGAR ↗